

Recombinant Human Erythropoietih Injection

Description

rh-EPO is a genetic engineering product by DNA techniques, which enables human EPO genes expressed in CHO cells, and followed by the process of the cell cultivation and protein purification processes.

The recombinant Human Erythropoietin is identical to natural human EPO in the structures and biological characteristics.

Indication

- 1. Anemia resulted from renal function insufficiency, including hemodialysis and norhemodialysis.
- 2. Reduction of Allogeneic Blood Transfusion in Surgery Patients.
- 3. Treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemitherapy. It is not indicated for the trestment of anemia in cancer patients due to other factors such as iron or folate deficencies, hemolysis, or gastrointestinal bleeding, which should be managed appropriately.

Advantages

- 1.Use of pre-filled syringes can relieve the injection pain, prevent latrogenic infection, avoid the loss of 10% of dosage caused by daed space in traditional syringe and reduce the working amount of doctors and nurses.
- 2.Patients reduce the times of regular blood transfusion, thus reducing the risk of being infected with diseases transmitted through blood.
- 3. Three phases of clinical trial show that our EPO has total effectiveness of 88.5%, including obvious effectiveness of 51.5% and effectiveness of 37%.

Pharmaceutical particulars

- 1. Colorless and transparent liquid with pH6.9±0.5.
- 2. Dosage:2000IU,3000IU,4000IU,6000IU,10000IU/ml
- 3. Package:vial and pre-filled syringe
- 4. Standard: Current European Pharmacopoeia and internal requirements.

Shelf life and storage conditions

Finished products:store at 2-8°C for two and a half years

API(concentrated solution):store at 2-8°C for two years